Status:
COMPLETED
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Pregnancy
Eligibility:
All Genders
13+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their infants can help reduce the chance that a mother will give HIV to her baby dur...
Detailed Description
NVP has several properties that make it an attractive candidate for antiretroviral therapy to interrupt HIV-1 transmission in the intrapartum and early postpartum period. The pharmacokinetic profile s...
Eligibility Criteria
Inclusion Criteria
You may be eligible for this study if you:
- Are an HIV-positive pregnant woman.
- Have been pregnant for at least 28 weeks.
- Are at least 13 years of age (consent of parent or guardian is required if under 18).
Exclusion Criteria
You will not be eligible for this study if:
- You intend to breast-feed.
- You are allergic to benzodiazepines (a type of tranquilizer).
- You have a liver disorder.
- You have received nonnucleoside reverse transcriptase inhibitors (NNRTIs), a class of anti-HIV drugs.
- You refuse to take ZDV.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
May 1 2001
Estimated Enrollment :
2009 Patients enrolled
Trial Details
Trial ID
NCT00001135
End Date
May 1 2001
Last Update
November 1 2021
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ of Alabama at Birmingham - Pediatric
Birmingham, Alabama, United States, 35233
2
UCSD Med Ctr / Pediatrics / Clinical Sciences
La Jolla, California, United States, 920930672
3
UCLA Med Ctr / Pediatric
Los Angeles, California, United States, 900951752
4
UCSF / Moffitt Hosp - Pediatric
San Francisco, California, United States, 941430105